Only one of four patients persisted with Novo Nordisk's (NVO) newer GLP-1 drugs, Wegovy or Ozempic, two years after taking ...
Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular ...
People taking compounded versions of Ozempic have been overdosing on the drug, the U.S. Food and Drug Administration ...
The FDA is warning healthcare providers of dosing errors associated with compounded versions of semaglutide, the active ingredient in Ozempic, Rybelsus and Wegovy.
Researchers from Monell Chemical Senses Center have identified a specific population of neurons in the brain that could be ...
Smokers with diabetes or obesity who take semaglutide (Ozempic/Wegovy) might reap an added benefit: Help in quitting ...
Who should receive Ozempic and GLP-1 drugs given their high demand and limited supply? Experts debate prioritizing those with ...
The next wave of obesity drugs could help people lose even more weight—and make some pharma companies a fortune.
Noom, Calibrate, and Embla tell customers they can stop taking GLP-1s and keep off the weight they’ve lost. Doctors and drug manufacturers disagree.
Share on Pinterest GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound can affect people differently. BONNINSTUDIO/Stocksy United Misconceptions about the benefits and risks of GLP-1 drugs like ...
After filing 13 lawsuits in 2023 claiming trademark infringement, deceptive trade practices, and false advertising related to ...
Robert Pearl A whopping one in eight U.S. adults have taken GLP-1 drugs like Wegovy and Ozempic for weight loss and related conditions. Their popularity and efficacy have sparked a ...